Induction of oral tolerance in splenocyte recipients toward pretransplant antigens ameliorates chronic graft versus host disease in a murine model.
Chronic graft versus host disease (cGVHD) is a major complication that can develop after bone marrow transplantation. It involves an immune-mediated attack by transplanted donor lymphocytes, and often results in inflammatory damage of host target organs. Immune hyporesponsiveness induced by oral antigen administration has been recently shown to prevent the development of cGVHD in a murine model. The aim of this study was to evaluate whether tolerance induction in bone marrow transplant (BMT) recipients after transplantation, toward their pretransplant antigens, can alleviate preexisting cGVHD in a mouse model. cGVHD was generated by infusing 2.5 x 10(7) splenocytes from B10.D2 donor mice, to sublethally irradiated (6 Gy) BALB/c recipient mice, which differ by minor histocompatibility antigens. Transplantation resulted in cGVHD, with characteristic scleroderma-like cutaneous fibrosis, increased skin collagen content, decreased body weight, and hepatic and small bowel inflammation. Oral tolerance was induced by feeding recipient BALB/c mice with proteins extracted from BALB/c splenocytes for 11 days after B10.D2 splenocyte transplantation. Tolerance induction was evidenced by a significant reduction in mixed lymphocyte response of effector splenocytes from tolerant BALB/c mice transplanted with B10.D2 splenocytes against BALB/c target splenocytes. Oral tolerance decreased skin collagen deposits. Reduction of collagen alpha1(I) gene expression and skin collagen were shown by in situ hybridization and histochemistry, respectively. Liver and bowel biopsy specimens revealed less inflammation. Serum IL-10 levels were higher in tolerant mice than in controls, whereas IFNgamma was significantly reduced. Oral tolerance of BMT recipients toward their pretransplant antigens after splenocyte transplantation down-regulated the immune attack by transplanted cells, thus ameliorating cGVHD.
Ilan
Y
Y
Liver Unit, Department of Medicine, and Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Gotsman
I
I
Pines
M
M
Beinart
R
R
Zeira
M
M
Ohana
M
M
Rabbani
E
E
Engelhardt
D
D
Nagler
A
A
D000284:Administration, Oral; D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology*; D003094:Collagen / Q000032:analysis / Q000235:genetics; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology* / Q000517:prevention & control; D007165:Immunosuppression Therapy / Q000379:methods*; D016753:Interleukin-10 / Q000097:blood; D017710:Lymphocyte Transfusion; D051379:Mice; D008807:Mice, Inbred BALB C; D008815:Mice, Inbred Strains; D015778:Minor Histocompatibility Antigens / Q000276:immunology; D011506:Proteins / Q000008:administration & dosage; D012867:Skin / Q000276:immunology / Q000473:pathology; D013154:Spleen / Q000276:immunology*; D014916:Whole-Body Irradiation
D015778:Minor Histocompatibility Antigens; D011506:Proteins; D016753:Interleukin-10; D003094:Collagen